SANTA ANA, Calif.--(BUSINESS WIRE)--Irvine Scientific, a leading cell culture media/ medical device company for more than 40 years, announced their newly launched cell therapy PRIME-XV™ product portfolio as part of the company’s commitment to accelerate basic research and clinical applications in cell therapy and regenerative medicine. Using their expertise in cell culture media development, PRIME-XV™ products were designed to function as part of an integrated workflow solution in culturing primary cells, where all products have been pre-validated to decrease end user qualification time. Initially, PRIME-XV™ products will comprise of a serum-free medium for the expansion of human mesenchymal stromal/ stem cells (MSCs), biopreservation solutions and extracellular matrix proteins. However, Irvine Scientific intends to expand this product line to offer other cell culture media and reagents, such as stem cell qualified fetal bovine serum, tumorsphere and neural progenitor cell expansion media. Examples of existing PRIME-XV™ products include:
